Monograph Details
|
|
Neoplasms
> Retinoids
|
|
TARGRETIN GEL |
| Manufacturer |
|
Eisai Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Retinoid. |
| Generic Name |
|
Bexarotene 1%; gel. |
| Indications |
|
Cutaneous lesions in patients with CTCL (Stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies. |
| Children |
|
Not recommended. |
| Adults |
|
Apply once every other day for the 1st week; then increase frequency at weekly intervals to once daily, then twice daily, then 3 times daily, then 4 times daily based on lesion tolerance. Usual dosing frequency: 2–4 times daily; may reduce if application site toxicity occurs. Allow gel to dry. Do not occlude. |
| Contraindications |
|
Pregnancy (Cat.X). |
| Precautions |
|
Be fully familiar with this drug's toxicity before use. Counsel patients monthly about need for contraception. Women of childbearing potential: obtain reliable negative pregnancy test within 1 week of start; repeat monthly. Start therapy on 2nd or 3rd day of normal menstrual period. Use two effective forms of contraception 1 month prior to, during, and for 1 month after therapy. Max 1 month/Rx. Men with partners who are or may become pregnant: use condoms during and for at least 1 month after therapy. Hepatic or renal insufficiency. Discontinue temporarily if severe irritation occurs. Avoid sun, UV light, and mucosal membranes. Nursing mothers: not recommended. |
| Interactions |
|
Avoid concomitant products that contain DEET. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice). Caution with gemfibrozil. Limit Vit. A supplements to avoid toxicity. |
| Adverse Reactions |
|
Application site reactions (eg, rash, pruritus, skin disorders, pain, contact dermatitis). |
| How Supplied |
|
Gel—60g |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
